Featured Stories
FFRF Stops Kentucky Elementary School From Promoting Christian Events
MADISON, Wisconsin, Oct. 28 -- The Freedom From Religion Foundation issued the following news release:
* * *
October 27, 2026
FFRF stops Kentucky elementary school from promoting Christian events
The Freedom From Religion Foundation has successfully stopped a Kentucky public elementary school from sponsoring devotional events.
The swift resolution came just two days after FFRF contacted Pike County Schools to object to a religious "prayer walk" that Mullins Elementary School held.
A concerned district community member reported that Mullins Elementary organized, promoted and encouraged attendance
... Show Full Article
MADISON, Wisconsin, Oct. 28 -- The Freedom From Religion Foundation issued the following news release:
* * *
October 27, 2026
FFRF stops Kentucky elementary school from promoting Christian events
The Freedom From Religion Foundation has successfully stopped a Kentucky public elementary school from sponsoring devotional events.
The swift resolution came just two days after FFRF contacted Pike County Schools to object to a religious "prayer walk" that Mullins Elementary School held.
A concerned district community member reported that Mullins Elementary organized, promoted and encouraged attendanceat a religious "prayer walk" event on Aug. 2. A post on Mullins Elementary's official Facebook page invited the community to the event: "Join the Mullins School community to pray for every area of our school." It also quoted a New Testament verse, Philippians 4:6, saying "Do not worry. Instead, pray and ask God for what you need with a thankful heart."
FFRF requested that Pike County Schools cease organizing, promoting or encouraging attendance at religious events and ensure that future school-sponsored events are secular.
"Here, the district is displaying blatant favoritism towards religion over nonreligion by asking the school community to participate in a Christian prayer event," FFRF Patrick O'Reiley Legal Fellow Charlotte R. Gude wrote to the district.
The district serves a diverse population that consists of not only religious students, families, and employees, but also non-Christians including atheists, agnostics and those who are simply religiously unaffiliated. An invitation from the district to "join the school community to pray" sends an official message that unconstitutionally promotes religion, excluding all nonreligious district students and community members. Up to 38 percent of the American population is non-Christian, including the almost 30 percent that is nonreligious.
Just two days after receiving FFRF's complaint letter, the district responded with a renewed commitment to students' rights.
The general counsel of Pike County Schools informed FFRF that he had directly talked with the then-Mullins Elementary principal and instructed him "to speak with his staff about this issue and to refrain from organizing, promoting and encouraging attendance at religious events, and ensure that all future school-sponsored events are entirely secular." The district's counsel additionally pledged: "I will make every effort to ensure that our employees are not unlawfully or inappropriately indoctrinating students in religious matters."
FFRF commends Pike County Schools for its prompt and unequivocal response.
"Public schools exist to educate, not to indoctrinate. Parents and schoolchildren should never be inveighed by their public schools to pray," says FFRF Co-President Annie Laurie Gaylor. "Taxpayers of all religions and no religion support our public schools, so all should be welcome -- and nothing is more divisive than religion in our public schools."
FFRF is pleased that, thanks to a concerned community member who spoke up, Pike County Schools has taken concrete steps to make Mullins Elementary welcoming of all families -- regardless of their religious or nonreligious beliefs.
"We thank our complainant for bringing this violation to our attention and Pike County Schools for quickly addressing it," Gaylor adds.
* * *
The Freedom From Religion Foundation is a national nonprofit organization with over 40,000 members and several chapters nationwide, including hundreds of members and a chapter in Kentucky. FFRF's purposes are to protect the constitutional principle of separation between church and state, and to educate the public on matters relating to nontheism.
* * *
Original text here: https://ffrf.org/news/releases/ffrf-stops-kentucky-elementary-school-from-promoting-christian-prayer-event/
[Category: Religion]
Royal Marsden NHS Foundation Trust: New Treatment Combination Shows Promising Results in Recurrent Head and Neck Cancer
LONDON, England, Oct. 27 (TNSxrep) -- The Royal Marsden National Health Service Foundation Trust issued the following news:
* * *
New treatment combination shows promising results in recurrent head and neck cancer
77 per cent of patients with HPV-unrelated recurrent and/or metastatic head and neck squamous cell carcinoma saw their tumours respond to the treatment
25 October 2026
A treatment combination including the targeted therapy amivantamab shrank tumours in more than three-quarters of patients with a hard-to-treat form of recurrent and/or metastatic head and neck cancer, according to
... Show Full Article
LONDON, England, Oct. 27 (TNSxrep) -- The Royal Marsden National Health Service Foundation Trust issued the following news:
* * *
New treatment combination shows promising results in recurrent head and neck cancer
77 per cent of patients with HPV-unrelated recurrent and/or metastatic head and neck squamous cell carcinoma saw their tumours respond to the treatment
25 October 2026
A treatment combination including the targeted therapy amivantamab shrank tumours in more than three-quarters of patients with a hard-to-treat form of recurrent and/or metastatic head and neck cancer, according toresults from an international clinical trial.
Researchers from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust took part in the global study, which found that amivantamab, given alongside the immunotherapy pembrolizumab and chemotherapy, achieved tumour responses in 77 per cent of patients with HPV-unrelated recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC).
The findings, which were presented today at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, are particularly encouraging because the current first-line treatment of pembrolizumab plus chemotherapy shrinks tumours in 36 per cent of patients with recurrent and/or metastatic head and neck cancer.
The results come from Cohort 5 of the international OrigAMI-4 clinical trial, which is supported by The Royal Marsden Cancer Charity and is being conducted at 56 sites across 11 countries. The trial is evaluating amivantamab both as a standalone treatment and in combination with other therapies.
In earlier cohorts, investigators saw that tumours shrank in 42 per cent of patients treated with amivantamab alone and 56 per cent with amivantamab plus pembrolizumab.
HPV-unrelated cancers are typically harder to treat
Head and neck squamous cell carcinoma is the most common type of head and neck cancer. Patients whose cancer has spread to other parts of the body or returned after treatment often face poor outcomes, and many do not benefit from existing therapies.
Head and neck cancers can broadly be divided into HPV-related and HPV-unrelated disease. HPV-related cancers are caused by infection with human papillomavirus and generally have better outcomes. HPV-unrelated cancers are typically harder to treat and associated with poorer survival.
Researchers have been investigating whether amivantamab, a bispecific antibody that targets the cancer-driving proteins EGFR and MET, can improve outcomes for these patients.
One in 10 patients had no detectable cancer following treatment
Cohort 5 of the Phase Ib/II OrigAMI-4 study evaluated amivantamab in combination with pembrolizumab and chemotherapy as a first-line treatment for recurrent and/or metastatic disease in patients whose tumours expressed PD-L1.
In total, 30 patients received treatment and 29 were included in the analysis.
Among 22 patients with HPV-unrelated disease, 17 achieved a confirmed response, resulting in an objective response rate of 77 per cent. Three patients achieved a complete response, meaning no detectable cancer remained, while 14 achieved a partial response.
Four patients had stable disease and one experienced disease progression. At the time of analysis, 11 of the 17 patients who responded to treatment continued to see their tumour shrink or remain stable.
Among seven patients with HPV-positive oropharyngeal squamous cell carcinoma, two achieved a partial response, giving an objective response rate of 29 per cent.
The findings have led investigators to take this regimen forward into the global Phase III OrigAMI-5 study, which is comparing amivantamab, pembrolizumab and chemotherapy with standard treatment in patients with HPV-unrelated recurrent and/or metastatic HNSCC.
Combined regimen to be continued as a global phase III trial
"These findings are particularly encouraging because the strongest activity was seen in patients with HPV-unrelated disease, who typically have poorer outcomes and fewer effective treatment options than patients with HPV-related cancers," says Professor Kevin Harrington, Professor of Biological Cancer Therapies at The Institute of Cancer Research, London, and Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust.
"We observed tumour responses in 77 per cent of patients in this group. Current pembrolizumab-based chemotherapy has achieved response rates of around 36 per cent, so this level of activity is very exciting.
"The decision to take this regimen forward into a global Phase III trial reflects the confidence these results have given us and provides an important opportunity to determine whether it can improve outcomes for patients."
'As a mum of three young children, this trial gives me hope'
Holly, a 29-year-old Royal Marsden patient from County Durham, was diagnosed with stage one tongue cancer in April 2025, while pregnant with her third child. She underwent surgery to remove part of her tongue during pregnancy, followed by surgery to remove lymph nodes in her neck and six weeks of radiotherapy after giving birth. However, a year later, her cancer returned, and she was told it was incurable.
"When I was told my cancer was incurable and that there were no other treatment options available to me at my local hospital, I was desperate to find another way forward," says Holly.
"I contacted Professor Harrington at The Royal Marsden, whose open-minded approach and extensive knowledge gave me hope and made me excited about the possibility of joining the OrigAMI-5 trial. I started the triple-combination treatment in July.
"Scans have already shown a 60 per cent reduction in my cancer and the intense pain I was previously experiencing disappeared within the first few weeks of starting treatment.
"As a mum of three young children, being given another treatment option has meant everything to me. When I thought there was nothing else that could be done, the trial gave me hope."
The OrigAMI-4 trial is supported by The Royal Marsden Cancer Charity.
* * *
Original text here: https://www.royalmarsden.nhs.uk/news-and-events/news/new-treatment-combination-shows-promising-results-recurrent-head-and-neck
Rockefeller Foundation: All In for Jobs Aims To Mobilize $1 Billion, Connect 500,000 Americans to Good Jobs
NEW YORK, Oct. 27 -- The Rockefeller Foundation posted the following news release:
* * *
All In for Jobs Aims To Mobilize $1 Billion, Connect 500,000 Americans to Good Jobs
NEW YORK | October 26, 2026 -- Today, over 20 foundations and philanthropies launched a $1 billion initiative to connect Americans to good jobs and keep people working in the face of AI and automation. The initiative, called All In For Jobs, is rallying local and national leaders in philanthropy, business, and nonprofits to work with up to 250 communities across the country that have been hard-hit by economic change and now
... Show Full Article
NEW YORK, Oct. 27 -- The Rockefeller Foundation posted the following news release:
* * *
All In for Jobs Aims To Mobilize $1 Billion, Connect 500,000 Americans to Good Jobs
NEW YORK | October 26, 2026 -- Today, over 20 foundations and philanthropies launched a $1 billion initiative to connect Americans to good jobs and keep people working in the face of AI and automation. The initiative, called All In For Jobs, is rallying local and national leaders in philanthropy, business, and nonprofits to work with up to 250 communities across the country that have been hard-hit by economic change and nowface new challenges and opportunities as technology reshapes work.
Launch partners have committed over $800 million to date. Over the next five years All In For Jobs will identify 250 communities whose residents have lost their jobs over recent decades, or face new job losses to AI and automation, and work with local leaders to help people connect to good jobs and keep them.
"In communities across the nation, there are too many people who need jobs, and too many jobs that need people," said Derek Kilmer, Senior Vice President for U.S. Program and Policy at The Rockefeller Foundation. "Philanthropy has a unique role to play in helping people connect to jobs that are open right now, helping create new ones, and helping workers adapt and thrive as work evolves."
Rather than only creating new jobs from scratch, All In For Jobs is focusing on the missing links that keep people from jobs that are already open. Too often, a job sits unfilled because one practical barrier stands in the way: childcare a worker cannot afford and local businesses cannot provide, transportation that does not reach the job, or training that never connects to the roles employers are trying to fill. Finding and fixing those barriers, community by community, is the work All In For Jobs will focus on. The specific communities will be decided in the months ahead.
"AI and automation may be transforming work, but technology alone should not decide who benefits, who is left behind, or what happens to a community," said Tonya Allen, President of the McKnight Foundation. "The people closest to this transition must have the power, resources, and seat at the table to shape what comes next. All In For Jobs is about putting that principle into practice by investing in local workers, local leaders, and the connections that turn economic change into meaningful opportunity. The future is not finished, and communities should help write it."
Because this challenge requires many solutions, All In For Jobs intends to bring together leaders across fields -- from workforce development to early childhood education and elsewhere -- to find what works. To launch the effort, over 20 foundations have committed $800 million. The coalition is actively growing. Beginning in January 2027, partners will convene regularly to identify, test, and scale solutions.
"We've seen the lasting harm that job displacement can cause during periods of economic transition, particularly for low income and older workers," said Claire Casey, president of AARP Foundation. "We have an opportunity to make this transition different. We can build a more inclusive future where workers of all ages have the skills and opportunities to adapt and share in the prosperity this transformation can create."
"We don't have all the answers yet, but we're inviting people to the table to help find them," said Kilmer. "We're looking for leaders in philanthropy, business, and nonprofits who want to work together to keep America working."
To learn more or join the coalition, visit allinforjobs.org.
All In For Jobs is supported by:
* AARP Foundation
* Community Foundation of Greater Flint
* Google.org
* James S. McDonnell Foundation
* Ewing Marion Kauffman Foundation
* McKnight Foundation
* NextLadder Ventures
* The Rockefeller Foundation
* Stand Together
* Strada Education Foundation
* StriveTogether
* And +14 other organizations
* * *
About The Rockefeller Foundation
Investing $30 billion over the last 113 years to promote the well-being of humanity, The Rockefeller Foundation is a pioneering philanthropy built on unlikely partnerships and innovative solutions that deliver measurable results for people in the United States and around the world. We leverage scientific breakthroughs, artificial intelligence, and new technologies to make big bets across energy, food, health, and finance, including with our public charity, RF Catalytic Capital (RFCC). For more information, sign up for our newsletter at www.rockefellerfoundation.org/subscribe and follow us on X @RockefellerFdn, Instagram @rockefellerfdn, and LinkedIn @the-rockefeller-foundation.
* * *
Original text here: https://www.rockefellerfoundation.org/news/all-in-for-jobs-aims-mobilize-1-billion-500000-americans-good-jobs/
Reason Foundation: RFK Jr. is Right to Expand Consumer Access to Peptides
LOS ANGELES, California, Oct. 27 -- The Reason Foundation issued the following news:
* * *
RFK Jr. is right to expand consumer access to peptides
Allowing pharmacies to compound experimental peptides would give consumers a more accountable alternative to unregulated sellers.
Jeffrey A. Singer
Senior Fellow
October 26, 2026
Health and Human Services Secretary Robert F. Kennedy Jr. recently offered a sensible rationale for wanting to expand consumer access to experimental peptides, which have attracted growing interest among fitness enthusiasts and people seeking injury recovery, weight loss,
... Show Full Article
LOS ANGELES, California, Oct. 27 -- The Reason Foundation issued the following news:
* * *
RFK Jr. is right to expand consumer access to peptides
Allowing pharmacies to compound experimental peptides would give consumers a more accountable alternative to unregulated sellers.
Jeffrey A. Singer
Senior Fellow
October 26, 2026
Health and Human Services Secretary Robert F. Kennedy Jr. recently offered a sensible rationale for wanting to expand consumer access to experimental peptides, which have attracted growing interest among fitness enthusiasts and people seeking injury recovery, weight loss,and anti-aging treatments. During an appearance on Fox News' "The Will Cain Show," Oct. 20, he explained, "Americans are going to be buying these anyway." He said the administration wants a regulated marketplace where consumers receive what sellers claim to provide and factories undergo inspection.
Kennedy's comments come as the administration considers easing restrictions on pharmacies that compound customized medications containing certain peptides. He is on the right track. Letting pharmacies supply these products gives consumers a better chance of knowing what they are getting and holds suppliers accountable for what they sell.
Peptides are short chains of amino acids, the building blocks of proteins. Many act as chemical messengers, binding to receptors on cells and signaling them to release hormones or alter other bodily functions. Scientists can synthesize these molecules or modify them to produce specific effects. Physicians have prescribed peptide medicines for decades. Insulin is a familiar example. Semaglutide, sold as Ozempic and Wegovy, mimics a hormone that regulates appetite and blood sugar. Each peptide has its own effects, benefits, and risks.
At its July 23 and 24 meeting, the Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee considered seven experimental peptides for the list of substances pharmacies may use in compounding. FDA staff recommended against adding any of them, citing safety concerns and insufficient evidence of effectiveness. The advisory committee nevertheless recommended adding six. Those votes were recommendations and they did not themselves change the rules.
The market extends well beyond the seven peptides the committee considered. Promoters market BPC-157 and TB-500 for tissue repair, injury recovery, and pain relief. MOTS-c attracts interest for metabolic health, exercise performance, and longevity, while Semax is promoted for mental sharpness and brain health. Products such as CJC-1295 stimulate growth-hormone release and attract consumers seeking muscle growth and faster recovery. These are advertised or hoped-for benefits, and the supporting human evidence varies considerably. The FDA's July assessments describe substantial gaps in that evidence.
Retatrutide, often called "reta," has also attracted consumers seeking weight loss. It activates three hormone receptors involved in appetite and metabolism, compared with the single receptor targeted by semaglutide. Researchers are still testing retatrutide in clinical trials, and the FDA has not approved it, although some sellers already offer products bearing its name. The FDA says retatrutide cannot be used in compounding under current federal law. For ordinary pharmacy compounding, the law generally requires bulk ingredients to meet an applicable U.S. Pharmacopeia standard, be components of FDA-approved medicines, or appear on an FDA list of permitted substances. Retatrutide currently meets none of those conditions. It was not among the seven peptides considered at the July meeting.
Consumers may obtain experimental peptides through wellness clinics, telehealth services, and some compounding pharmacies that prepare customized medications. Others buy directly from online sellers who label their products "research use only" yet market them for human use. Availability does not guarantee that a product complies with federal compounding rules. Social media has amplified the promised benefits, often giving consumers testimonials with little discussion of risks.
The evidence varies considerably. A small retrospective study of BPC-157 injections for knee pain reported improvement but lacked a randomized comparison group. Such findings justify further research but do not tell us whether the peptide caused the improvement. A controlled study of CJC-1295 found that it increased growth hormone and a related growth signal. That does not demonstrate faster injury recovery or longer life. Nor can favorable findings from cells or animals tell us whether a particular human dose provides more benefit than risk.
Some peptides have much stronger clinical evidence. Randomized trials of tesamorelin found reductions in abdominal visceral fat among patients with HIV. A recently published phase 3 trial of retatrutide, involving 1,152 adults with obesity or overweight and type 2 diabetes, found an average weight loss of 18.8 percent at 80 weeks in the highest-dose group, compared with 5.1 percent with placebo. Gastrointestinal adverse effects were more common with retatrutide. These results support a specific use in the studied population. They do not establish that every vial sold online contains the trial drug at the stated strength or purity.
Consumers deserve candid explanations of these distinctions. The FDA has raised concerns about impurities, immune reactions, and missing safety data for several experimental peptides. Reliable manufacturing cannot eliminate a drug's inherent risks or prove its effectiveness, but it can reduce the additional risks of contamination, incorrect ingredients, and inaccurate dosing.
The Center for Science in the Public Interest has urged the FDA to reject the committee's recommendations. Its concerns about evidence, safety, and financial conflicts among committee members deserve attention. But preserving restrictions also has consequences. Adults who understand the uncertainties may still choose to use these products. Blocking pharmacies from supplying them leaves those consumers with fewer accountable sources and can steer them toward sellers whose manufacturing practices and products are harder to verify.
Kennedy recognizes that demand will persist. Permitting compounding pharmacies to prepare these products under standards for identity, potency, and sterile production would offer willing buyers a more accountable alternative. Pharmacies and clinicians should explain the limits of the evidence, and suppliers should be held accountable for fraud and negligence. Allowing access would not certify every claimed benefit or relieve sellers of responsibility for the products they provide.
Autonomous adults should be free to weigh uncertain benefits against known and unknown risks. Compounding allows clinicians and pharmacists to tailor a drug's dose or formulation to an individual patient's needs. Preserving that option gives patients and clinicians more room to make treatment decisions as researchers continue gathering evidence. Physicians can advise them, researchers can improve the evidence, and regulators can warn them about hazards. None of those roles requires public officials to have the final say over a competent adult's willingness to try an experimental product. The Center for Science in the Public Interest gives too little weight to that autonomy and to the risks of keeping willing buyers in an underground market.
Kennedy recognizes that consumers benefit from identifiable products and accountable suppliers. His approach points to a practical principle for drug policy: preserve legal access, give consumers accurate information, and hold suppliers accountable for fraud and negligence. Pharmacological differences warrant specific warnings and careful monitoring. Competent adults should retain the authority to decide which risks they accept.
The FDA should permit pharmacies to compound these experimental peptides under standards that minimize contamination and misrepresentation. Blocking accountable suppliers leaves willing buyers with fewer reliable sources and exposes them to additional risks. That reasoning also applies to other substances sold on black or gray markets. Kennedy is on the right track with peptides. His administration should apply that insight consistently.
* * *
Jeffrey A. Singer is a senior fellow at Reason Foundation.
* * *
Original text here: https://reason.org/commentary/rfk-jr-is-right-to-expand-consumer-access-to-peptides/
Foundation for Economic Education Issues Commentary: New Technology Can Bring Benefits to Everyone
DETROIT, Michigan, Oct. 27 -- The Foundation for Economic Education issued the following commentary:
* * *
October 26, 2026
Who's Afraid of AI?
Ella Dawson
New technology can bring benefits to everyone.
-
A former employee of the AI firm Anthropic, Jacob Coxon, recently went viral for being a whistleblower about the future of artificial intelligence. "I believe that if we don't slow down at the current rate of progress, there is a strong chance that we could all die in the immediate future," he said. Coxon worries that AI developers are racing through self-improving superintelligence, resulting
... Show Full Article
DETROIT, Michigan, Oct. 27 -- The Foundation for Economic Education issued the following commentary:
* * *
October 26, 2026
Who's Afraid of AI?
Ella Dawson
New technology can bring benefits to everyone.
-
A former employee of the AI firm Anthropic, Jacob Coxon, recently went viral for being a whistleblower about the future of artificial intelligence. "I believe that if we don't slow down at the current rate of progress, there is a strong chance that we could all die in the immediate future," he said. Coxon worries that AI developers are racing through self-improving superintelligence, resultingin technology that can hack anything, revolutionize any field overnight, and acquire real power and resources.
Both Sam Altman, CEO of OpenAI, and Elon Musk, CEO of xAI, have agreed with Coxon's concerns, and called for both independent monitoring of AI development and government regulation. There has been some suspicion as to the devious motivations of these businessmen. Why would these AI developers call for something that would, supposedly, cut into their profits and progress? More laissez-faire commentators argue that these regulations would actually do the opposite for big businesses by blocking out small startup competitors who can't compete with rising red tape.
In connection with these assertions, the AI debate is often incorrectly accepted under the premise that it only benefits the rich. Supposedly, data centers cut into everyday Americans' housing and water costs, Flock cameras gather personal information valuable to those rich enough to obtain it, and social media is full of anti-AI posts and comments with most bemoaning that their jobs will soon be taken by robots. And it's all because of evil Trump-loving billionaires... or is it?
"The rich in Ancient Greece would have benefited hardly at all from modern plumbing: running servants replaced running water," Milton and Rose Friedman wrote in Free to Choose. "Television and radio--the patricians of Rome could enjoy the leading musicians and actors in their home, could have the leading artists as domestic retainers." This point from the Friedmans isn't unique to plumbing and radio, but applies to many types of tech, including AI.
I use ChatGPT for things like meal- and garden-planning, research, and interpreting the writings of crazy philosophers like Jacques Derrida. Similar to the rich in Ancient Greece, the wealthy today have chefs, gardeners, and researchers. The rich don't benefit from AI in the same way ordinary people do. For every common person who hates AI, there is a common person using AI. On college campuses, 86% of students use AI in their studies. One in four use it daily. These same students boo commencement speakers who talk about AI positively. In the workplace, 38% of adults report using chatbots for everyday tasks, and outside of the office, about half of US adults report using chatbots in general. If we're so worried about AI stealing our jobs, why do 38% of employees use it at work?
There are certainly legitimate questions as to whether or not this use of AI actually benefits people. As the argument goes, the more we outsource human activities to robots, the less human we become. But it does beg the question: If there are so many problems and dangers with AI, why do so many use it? Virtually every invention has outsourced a human activity to a machine. There are massive cons to running water, guns, television, radio, cell phones, and social media. But again: Why would so many people use these devices if they didn't believe they benefited their life in some way?
"The real result of the machine is to increase production, to raise the standard of living, to increase economic welfare," Henry Hazlitt wrote in Economics in One Lesson. "Full employment--very full employment; long, weary, back-breaking employment--is characteristic of precisely the nations that are most retarded industrially."
In Milton Friedman's vision of the world, as Thomas Sowell wrote in his book A Conflict of Visions, "exploitative situations have been seen as more effectively eliminated by the systemic characteristics of a competitive economy than by the deliberate intervention of political leaders in complex economic processes that they cannot comprehend."
In other words, if the rich are prone to exploit others, this is better resolved by a free-market competitive economy than by government regulation. "Intervention" in "complex economic processes that they cannot comprehend" is particularly true of artificial intelligence. How can you regulate something that is always changing, and most politicians likely do not comprehend?
The rich always have more resources at their disposal than do the poor, albeit with much more risk. But, AI, like many other inventions, gives the ordinary person the resources that previously may have been only available to the rich.
"Human nature will not change," journalist Matt Ridley wrote in his book The Rational Optimist. "The same old dramas of aggression and addiction, of infatuation and indoctrination, of charm and harm, will play out, but in an ever more prosperous world."
* * *
Ella Dawson
Ella Dawson is a freelance journalist and history writer living in Utah. She previously wrote for Spectator World. Follow her on Substack.
* * *
Original text here: https://fee.org/articles/whos-afraid-of-ai/
Breakthrough T1D Presents Dr. Peter Thompson with 2026 Dr. Robert Goldstein Award
NEW YORK, Oct. 27 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, posted the following news release:
* * *
Breakthrough T1D Presents Dr. Peter Thompson with 2026 Dr. Robert Goldstein Award
*
Award recognizes outstanding efforts in type 1 diabetes research
New York, Oct. 27, 2026--Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly announces Peter Thompson, Ph.D. as the recipient of the 2026 Dr. Robert Goldstein Award in recognition of his notable contributions to T1D research.
Named for Dr.
... Show Full Article
NEW YORK, Oct. 27 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, posted the following news release:
* * *
Breakthrough T1D Presents Dr. Peter Thompson with 2026 Dr. Robert Goldstein Award
*
Award recognizes outstanding efforts in type 1 diabetes research
New York, Oct. 27, 2026--Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly announces Peter Thompson, Ph.D. as the recipient of the 2026 Dr. Robert Goldstein Award in recognition of his notable contributions to T1D research.
Named for Dr.Robert Goldstein, who played a key role in developing Breakthrough T1D's Research department and served as chief scientific officer for Breakthrough International and Breakthrough T1D Canada for decades, the award recognizes notable early career T1D researchers who show great promise for future work in the field.
Dr. Thompson is associate professor of physiology and pathophysiology in the University of Manitoba's Max Rady College of Medicine and research scientist at the Children's Hospital Research Institute of Manitoba. He completed his Ph.D. in medical genetics in 2016 studying stem cell biology at the University of British Columbia, and his postdoctoral training in islet biology and T1D at the University of California San Francisco Diabetes Center in 2020. Dr. Thompson established his independent research program as an assistant professor at University of Manitoba in 2020.
Dr. Thompson's research has focused on senescence as a mechanism contributing to beta cell dysfunction in T1D, and as a potential target for developing disease-modifying therapies. His work highlights the active role beta cells play in disease progression and points to stress response pathways that may offer long term therapeutic opportunities. Dr. Thompson's research program is funded by major national grants including from Breakthrough T1D Canada, the Canadian Institutes of Health Research, and Diabetes Canada.
"Although insulin was discovered more than 100 years ago and is still a lifesaving medication today, we are only beginning to understand the complexities of how T1D develops and how to safely and effectively replace lost beta cells in people living with the disease," said Thompson. "As a result of our research, we hope to develop therapies that can slow or halt disease progression before a T1D diagnosis and, eventually, prevent T1D. Our work will also support ongoing efforts in the field to provide safe and effective cell-replacement therapies for people living with T1D."
"Breakthrough T1D is proud to present this award to Dr. Thompson and honor his innovative contributions that have helped advance our collective understanding of type 1 diabetes disease progression," said Breakthrough T1D Chief Scientific Officer Sanjoy Dutta, Ph.D. "His discoveries surrounding beta cells in type 1 diabetes have provided clear research insights and pathways for developing new T1D therapies. This work has been integral to Breakthrough T1D's mission and will continue to have a tremendous impact on the future of type 1 diabetes treatment and the broader T1D community."
Breakthrough T1D research award recipients were recognized at a ceremony in Philadelphia earlier in October 2026.
As the leading global type 1 diabetes research and advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition.
About Type 1 Diabetes (T1D)
T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short and long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death. Globally, it impacts 9.5 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.
***
Original text here: https://www.breakthrought1d.org/for-the-media/press-releases/breakthrough-t1d-presents-dr-peter-thompson-with-2026-dr-robert-goldstein-award/
Breakthrough T1D Honors Dr. William Tamborlane with the 2026 Breakthrough T1D David Rumbough Award
NEW YORK, Oct. 27 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, posted the following news release:
* * *
Breakthrough T1D Honors Dr. William Tamborlane with the 2026 Breakthrough T1D David Rumbough Award
*
Award recognizes outstanding efforts in type 1 diabetes research
New York, Oct. 27, 2026--Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly announces William Tamborlane, M.D., Ph.D. as the recipient of the 2026 Breakthrough T1D David Rumbough Award in recognition of his remarkable accomplishments
... Show Full Article
NEW YORK, Oct. 27 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, posted the following news release:
* * *
Breakthrough T1D Honors Dr. William Tamborlane with the 2026 Breakthrough T1D David Rumbough Award
*
Award recognizes outstanding efforts in type 1 diabetes research
New York, Oct. 27, 2026--Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly announces William Tamborlane, M.D., Ph.D. as the recipient of the 2026 Breakthrough T1D David Rumbough Award in recognition of his remarkable accomplishmentsin T1D research.
The Breakthrough T1D David Rumbough Award acknowledges an individual who has made outstanding achievements in the field of T1D that have significantly accelerated the Breakthrough T1D mission.
Dr. Tamborlane had a distinguished career as an academic pediatric endocrinologist and diabetes researcher. His groundbreaking study of the portable insulin pump for individuals with T1D and dedication to the families who participated in the rigorous research protocols changed the trajectory of many people's lives and had a tremendous impact on the field. He understood, with great conviction, that the achievement of glycemic targets would prevent long-term complications--a principle later confirmed unequivocally by the landmark Diabetes Control and Complications Trial (DCCT), the results of which were published in the New England Journal of Medicine in 1993. At the time of his retirement from Yale School of Medicine, his curriculum vitae listed over one thousand articles, book chapters, and guidance documents.
Over the course of his career, he received over 25 national and international honors, including the Juvenile Diabetes Research Foundation (JDRF, now Breakthrough T1D) Mary Tyler Moore and S. Robert Levine, M.D. Excellence in Clinical Research Award in 2006 and the American Diabetes Association Outstanding Achievement in Clinical Diabetes Research Award in 2017.
"Dr. Tamborlane's pioneering leadership in automated insulin delivery systems and diabetes technologies research helped transform type 1 diabetes treatment and made living with the condition more manageable for those who face it," said Breakthrough T1D Chief Scientific Officer Sanjoy Dutta, Ph.D. "Breakthrough T1D is honored to recognize Dr. Tamborlane and his exceptional legacy and career, which was punctuated by a steadfast dedication to the type 1 diabetes and research communities."
As the leading global type 1 diabetes research and advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition.
About Type 1 Diabetes (T1D)
T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short and long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death. Globally, it impacts 9.5 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.
***
Original text here: https://www.breakthrought1d.org/for-the-media/press-releases/breakthrough-t1d-honors-dr-william-tamborlane-with-the-2026-breakthrough-t1d-david-rumbough-award/
